Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Gastro Oesophageal Reflux Disease Forecast in 19 Major Markets 2017-2027 - Research and Markets

Research and Markets
Posted on: 03 Oct 17

The "Gastro Oesophageal Reflux Disease Forecast in 19 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Gastro-oesophageal reflux disease (GORD) is a common disorder of the upper gastrointestinal tract. According to the most recent definition, it is a condition occurring when reflux of gastric contents causes troublesome symptoms and/or complications. Based on endoscopy findings, the disease is broadly classified into two subtypes: demonstrating oesophageal mucosal damage (Erosive Reflux Disease, ERD) or no mucosal damage (Non-Erosive Reflux Disease, NERD). Injury to the oesophagus that may be associated with GORD is due to re?ux of gastric acid and pepsin, but also bile in the case of duodenogastric re?ux.

This report provides the current prevalent population for GORD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Norway, Sweden, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, the two subtypes of the disease (ERD and NERD), as well as several of the main symptoms and co-morbidities of GORD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GORD include:

  • Globus
  • Non-cardiac chest pain
  • Asthma
  • Dysphagia
  • Dyspepsia
  • Chronic cough

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Comorbid Conditions / Features Associated With the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Gastro-Oesophageal Reflux Disease

10. Features of Gastro-Oesophageal Reflux Disease Patients

11. Comorbid Conditions of Gord Patients

12. Abbreviations Used in the Report

13. Other Publications

14. Patient-Based Databases

15. Patient-Based Offering

16. Online Pricing Data & Platforms

17. References

18. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/3pvfwx/gastro

View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005661/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.